PortalPublikationenHeterogeneity of luminal breast cancer characterised by immu...

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers

Standard

Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. / Sung, Hyuna; Garcia-Closas, Montserrat; Chang-Claude, Jenny; Blows, Fiona M; Ali, H Raza; Figueroa, Jonine; Nevanlinna, Heli; Fagerholm, Rainer; Heikkilä, Päivi; Blomqvist, Carl; Giles, Graham G; Milne, Roger L; Southey, Melissa C; McLean, Catriona; Mannermaa, Arto; Kosma, Veli-Matti; Kataja, Vesa; Sironen, Reijo; Couch, Fergus J; Olson, Janet E; Hallberg, Emily; Olswold, Curtis; Cox, Angela; Cross, Simon S; Kraft, Peter; Tamimi, Rulla M; Eliassen, A Heather; Schmidt, Marjanka K; Bolla, Manjeet K; Wang, Qin; Easton, Douglas; Howat, William J; Coulson, Penny; Pharoah, Paul Dp; Sherman, Mark E; Yang, Xiaohong R.

in: BRIT J CANCER, Jahrgang 114, Nr. 3, 02.02.2016, S. 298-304.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sung, H, Garcia-Closas, M, Chang-Claude, J, Blows, FM, Ali, HR, Figueroa, J, Nevanlinna, H, Fagerholm, R, Heikkilä, P, Blomqvist, C, Giles, GG, Milne, RL, Southey, MC, McLean, C, Mannermaa, A, Kosma, V-M, Kataja, V, Sironen, R, Couch, FJ, Olson, JE, Hallberg, E, Olswold, C, Cox, A, Cross, SS, Kraft, P, Tamimi, RM, Eliassen, AH, Schmidt, MK, Bolla, MK, Wang, Q, Easton, D, Howat, WJ, Coulson, P, Pharoah, PD, Sherman, ME & Yang, XR 2016, 'Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers', BRIT J CANCER, Jg. 114, Nr. 3, S. 298-304. https://doi.org/10.1038/bjc.2015.437

APA

Sung, H., Garcia-Closas, M., Chang-Claude, J., Blows, F. M., Ali, H. R., Figueroa, J., Nevanlinna, H., Fagerholm, R., Heikkilä, P., Blomqvist, C., Giles, G. G., Milne, R. L., Southey, M. C., McLean, C., Mannermaa, A., Kosma, V-M., Kataja, V., Sironen, R., Couch, F. J., ... Yang, X. R. (2016). Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. BRIT J CANCER, 114(3), 298-304. https://doi.org/10.1038/bjc.2015.437

Vancouver

Sung H, Garcia-Closas M, Chang-Claude J, Blows FM, Ali HR, Figueroa J et al. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. BRIT J CANCER. 2016 Feb 2;114(3):298-304. https://doi.org/10.1038/bjc.2015.437

Bibtex

@article{92ecc70892844d83b5313482230be231,
title = "Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers",
abstract = "BACKGROUND: Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.METHODS: We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case-case comparison was performed using unconditional logistic regression.RESULTS: Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.CONCLUSIONS: Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.",
author = "Hyuna Sung and Montserrat Garcia-Closas and Jenny Chang-Claude and Blows, {Fiona M} and Ali, {H Raza} and Jonine Figueroa and Heli Nevanlinna and Rainer Fagerholm and P{\"a}ivi Heikkil{\"a} and Carl Blomqvist and Giles, {Graham G} and Milne, {Roger L} and Southey, {Melissa C} and Catriona McLean and Arto Mannermaa and Veli-Matti Kosma and Vesa Kataja and Reijo Sironen and Couch, {Fergus J} and Olson, {Janet E} and Emily Hallberg and Curtis Olswold and Angela Cox and Cross, {Simon S} and Peter Kraft and Tamimi, {Rulla M} and Eliassen, {A Heather} and Schmidt, {Marjanka K} and Bolla, {Manjeet K} and Qin Wang and Douglas Easton and Howat, {William J} and Penny Coulson and Pharoah, {Paul Dp} and Sherman, {Mark E} and Yang, {Xiaohong R}",
year = "2016",
month = feb,
day = "2",
doi = "10.1038/bjc.2015.437",
language = "English",
volume = "114",
pages = "298--304",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers

AU - Sung, Hyuna

AU - Garcia-Closas, Montserrat

AU - Chang-Claude, Jenny

AU - Blows, Fiona M

AU - Ali, H Raza

AU - Figueroa, Jonine

AU - Nevanlinna, Heli

AU - Fagerholm, Rainer

AU - Heikkilä, Päivi

AU - Blomqvist, Carl

AU - Giles, Graham G

AU - Milne, Roger L

AU - Southey, Melissa C

AU - McLean, Catriona

AU - Mannermaa, Arto

AU - Kosma, Veli-Matti

AU - Kataja, Vesa

AU - Sironen, Reijo

AU - Couch, Fergus J

AU - Olson, Janet E

AU - Hallberg, Emily

AU - Olswold, Curtis

AU - Cox, Angela

AU - Cross, Simon S

AU - Kraft, Peter

AU - Tamimi, Rulla M

AU - Eliassen, A Heather

AU - Schmidt, Marjanka K

AU - Bolla, Manjeet K

AU - Wang, Qin

AU - Easton, Douglas

AU - Howat, William J

AU - Coulson, Penny

AU - Pharoah, Paul Dp

AU - Sherman, Mark E

AU - Yang, Xiaohong R

PY - 2016/2/2

Y1 - 2016/2/2

N2 - BACKGROUND: Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.METHODS: We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case-case comparison was performed using unconditional logistic regression.RESULTS: Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.CONCLUSIONS: Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.

AB - BACKGROUND: Luminal A breast cancer defined as hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative is known to be heterogeneous. Previous study showed that luminal A tumours with the expression of basal markers ((cytokeratin (CK) 5 or CK5/6) or epidermal growth factor receptor (EGFR)) were associated with poorer prognosis compared with those that stained negative for basal markers. Prompted by this study, we assessed whether tumour characteristics and risk factors differed by basal marker status within luminal A tumours.METHODS: We pooled 5040 luminal A cases defined by immunohistochemistry (4490 basal-negative ((CK5 (or CK5/6))- and EGFR-) and 550 basal-positive ((CK5 (or CK5/6+)) or EGFR+)) from eight studies participating in the Breast Cancer Association Consortium. Case-case comparison was performed using unconditional logistic regression.RESULTS: Tumour characteristics and risk factors did not vary significantly by the expression of basal markers, although results suggested that basal-positive luminal tumours tended to be smaller and node negative, and were more common in women with a positive family history and lower body mass index.CONCLUSIONS: Most established breast cancer risk factors were similar in basal-positive and basal-negative luminal A tumours. The non-significant but suggestive differences in tumour features and family history warrant further investigations.

U2 - 10.1038/bjc.2015.437

DO - 10.1038/bjc.2015.437

M3 - SCORING: Journal article

C2 - 26679376

VL - 114

SP - 298

EP - 304

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 3

ER -